| 王西建,李 琨,焦宁波,亢晓燕,李雅妹.艾司西酞普兰联合解郁安神颗粒治疗抑郁症的效果及对患者血清IL-2、IL-6、TNF-α、Hcy水平的影响[J].,2018,(24):4790-4793 |
| 艾司西酞普兰联合解郁安神颗粒治疗抑郁症的效果及对患者血清IL-2、IL-6、TNF-α、Hcy水平的影响 |
| Clinical Effects of Escitalopram Combined with Jieyu Anshen Granule on the Patients with Depression and the Serum IL-2, IL-6, TNF-α and Hcy Levels |
| 投稿时间：2018-03-01 修订日期：2018-03-16 |
| DOI：10.13241/j.cnki.pmb.2018.24.043 |
| 中文关键词: 司西酞普兰 解郁安神颗粒 抑郁症 白介素-2 白介素-6 肿瘤坏死因-α 同型半胱氨酸 |
| 英文关键词: Stilipramine Jieyu Anshen granule Depression Interleukin-2 Interleukin-6 Tumor necrosis-alpha Homocysteine |
| 基金项目:陕西省教育厅科研项目(12JK1027) |
|
| 摘要点击次数: 604 |
| 全文下载次数: 223 |
| 中文摘要: |
| 摘要 目的：分析艾司西酞普兰联合解郁安神颗粒对抑郁症患者的疗效及对血清血清白介素-2(IL-2)、白介素-6(IL-6)、和肿瘤坏死因-α(TNF-α)、同型半胱氨酸(Hcy)水平的影响。方法：选择2015年6月至2016年6月我科收治的精神症合并抑郁患者72例为研究对象，平均分为两组。观察组36例采用解郁安神颗粒联合艾司西酞普兰药物治疗，而对照组36例仅采用艾司西酞普兰药物治疗。治疗7周后，分析和比较两组患者的临床疗效、治疗前后HAMD-17评分、血清IL-2、IL-6、TNF-α、Hcy水平的变化及不良反应的发生情况。结果：治疗7周后，观察组患者的痊愈率为55.56%，显效率为97.22%；而对照组的痊愈率为33.33%，显效率为69.44%，观察组痊愈率和显效率均显著高于对照组(P<0.05)；观察组患者的HAMD-17评分显著低于对照组(P<0.05)。两组患者治疗前的血清IL-2、IL-6、TNF-α、Hcy水平比较差异均无明显统计学意义(P>0.05)，观察组患者治疗7周后的血清TNF-α(23.23±4.34 ng/L)、IL-6 (1.43±0.68 ng/L)、IL-2 (35.34±6.33 ng/L)与Hcy (18.23±0.91 ng/L)水平均明显低于对照组(P<0.05)。在7周疗后，观察组患者不良反应的发生率为8.34%，而对照组不良反应的发生率为38.88%，显著高于观察组(P=0.0156)。结论：艾司西酞普兰联合解郁安神颗粒治疗抑郁症患者可以明显提高临床疗效和安全性，可能与其降低血清IL-2、IL-6、TNF-α、Hcy水平有关。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of escitalopram combined with Jieyu Anshen granule on the depression and the serum IL-2, IL-6, TNF-α and Hcy levels. Methods: A total of 72 patients with psychotic and depression who were enrolled in our depart- ment from June 2015 to June 2016 were divided into two groups. 36 cases in the observation group were treated with Jieyu Anshen gran- ule combined with escitalopram drug treatment, while 36 cases in the control group were treated with escitalopram. After 7 weeks of treatment, the clinical efficacy of two groups was analyzed and compared. The levels of HAMD-17, serum IL-2, IL-6, TNF-α and Hcy levels before and after treatment and the incidence of adverse reactions were compared between two groups. Results: After 7 weeks of treatment, the cure rate was 55.56% and the effective rate was 97.22% in the observation group, which were 33.33%, 69.44% in the con- trol group respectively. The cure rate and markedly effective rate in the observation group were significantly higher than those in the con- trol group(P<0.05); The HAMD-17 score of observation group was significantly lower than that of the control group (P<0.05). There was no significant difference in the serum IL-2, IL-6, TNF-α and Hcy levels between the two groups before treatment(P>0.05). The serum levels of TNF-α(23.23±4.34 ng/L), IL-6 (1.43±0.68 ng/L), IL-2 (35.34±6.33 ng/L) and Hcy (18.23±0.91 ng/L) after 7 weeks of treat- ment in the observation group were significantly lower than those in the control group(P<0.05). After 7 weeks of treatment, the incidence of adverse reactions was 8.34% in the observation group and 38.88% in the control group, which was significantly higher in the observa- tion than that of the observation group(P=0.0156). Conclusion: Escitalopram combined with Jiyu Anshen granule could significantly im- prove the clinical efficacy and safety of patients with depression, which might be related to the decrease of serum IL-2, IL-6, TNF-α and Hcy levels. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
